Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Micafungin
Drug ID BADD_D01455
Description Micafungin is an antifungal drug. It belongs to the antifungal class of compounds known as echinocandins and exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall.
Indications and Usage Indicated for the treatment of candidemia, acute disseminated candidiasis, and certain other invasive Candida infections, as well as esophageal candidiasis, and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. Micafungin is also used as an alternative for the treatment of oropharyngeal candidiases and has been used with some success as primary or salvage therapy, alone or in combination with other antifungals, for the treatment of invasive aspergillosis. Indicated for the prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.
Marketing Status approved; investigational
ATC Code J02AX05
DrugBank ID DB01141
KEGG ID D08218
MeSH ID D000077551
PubChem ID 477468
TTD Drug ID D06TOE
NDC Product Code 16714-301; 70710-1725; 60505-6120; 70771-1683; 60505-6119; 70771-1684; 42023-229; 16714-164; 70710-1724; 42023-230
UNII R10H71BSWG
Synonyms Micafungin | FK 463 | FK463 | FK-463 | Micafungin Sodium | Mycamine
Chemical Information
Molecular Formula C56H71N9O23S
CAS Registry Number 235114-32-6
SMILES CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)NC4CC(C(NC(=O)C5C(C(CN5C(=O)C(NC (=O)C(NC(=O)C6CC(CN6C(=O)C(NC4=O)C(C)O)O)C(C(C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)C(C C(=O)N)O)C)O)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pruritus23.03.12.001--
Pulmonary embolism24.01.06.001; 22.06.02.001--Not Available
Pyrexia08.05.02.0030.000404%
Rash23.03.13.001--Not Available
Renal failure20.01.03.005--Not Available
Renal tubular necrosis20.01.07.003--Not Available
Respiratory failure22.02.06.002; 14.01.04.0030.000150%
Seizure17.12.03.001--
Sepsis11.01.11.003--
Septic shock24.06.02.011; 11.01.11.004--Not Available
Shock24.06.02.002--Not Available
Sinus bradycardia02.03.03.0090.000374%
Skin disorder23.03.03.007--Not Available
Skin exfoliation23.03.07.003--Not Available
Skin necrosis23.03.03.011--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Stevens-Johnson syndrome11.07.01.005; 10.01.01.045; 23.03.01.007; 12.03.01.014--
Swelling face08.01.03.100; 23.04.01.018; 10.01.05.018--Not Available
Tachycardia02.03.02.007--Not Available
Thrombocytopenia01.08.01.0020.000329%Not Available
Thrombophlebitis24.01.02.001--Not Available
Thrombotic thrombocytopenic purpura01.08.01.005; 24.07.06.014; 23.06.01.011--
Torsade de pointes02.03.04.0050.000150%Not Available
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.006--
Tremor17.01.06.002--
Urethral disorder20.07.01.002--Not Available
Urinary tract disorder20.08.01.001--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Vomiting07.01.07.0030.000224%
White blood cell count decreased13.01.06.012--
The 5th Page    First    Pre   5 6 7    Next   Last    Total 7 Pages